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Abstract: Snake venom metalloproteinases (SVMPs) play key biological roles in prey immobilization
and digestion. The majority of these activities depend on the hydrolysis of relevant protein substrates
in the tissues. Hereby, we describe several isoforms and a cDNA clone sequence, corresponding to PII
SVMP homologues from the venom of the Central American pit viper Bothriechis lateralis, which have
modifications in the residues of the canonical sequence of the zinc-binding motif HEXXHXXGXXH.
As a consequence, the proteolytic activity of the isolated proteins was undetectable when tested on
azocasein and gelatin. These PII isoforms comprise metalloproteinase and disintegrin domains
in the mature protein, thus belonging to the subclass PIIb of SVMPs. PII SVMP homologues
were devoid of hemorrhagic and in vitro coagulant activities, effects attributed to the enzymatic
activity of SVMPs, but induced a mild edema. One of the isoforms presents the characteristic RGD
sequence in the disintegrin domain and inhibits ADP- and collagen-induced platelet aggregation.
Catalytically-inactive SVMP homologues may have been hitherto missed in the characterization of
snake venoms. The presence of such enzymatically-inactive homologues in snake venoms and their
possible toxic and adaptive roles deserve further investigation.
Keywords: snake venom metalloproteinases; PII SVMP homologues; disintegrin domain;
zinc-binding motif; hemorrhagic activity; platelet aggregation; proteinase activity
1. Introduction
Snake venom metalloproteinases (SVMPs) are abundant components in the venoms of
advanced snakes of the superfamily Colubroidea and play key roles in venom toxic and digestive
actions [1–3]. Together with the ADAMs and ADAMTs, SVMPs are classified within the M12 family
of metalloproteinases (subfamily M12B or reprolysin) [1], which, in turn, belong to the metzincin
superfamily of these proteinases. This superfamily is characterized by a canonical zinc-binding
sequence (HEXXHXXGXXH) followed by a Met-turn [4].
SVMPs have been classified into three classes on the basis of the domain composition (PI, PII
and PIII). All contain a signal sequence, a prodomain and a metalloproteinase domain. In the case of the
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PI class, the mature protein has only the metalloproteinase domain, while the PII class has, in addition
to the catalytic domain, a disintegrin (Dis) domain, which may be proteolytically processed, giving
rise to a free disintegrin, that in most cases hosts the canonical RGD motif [5]. In turn, PIII class SVMPs
have disintegrin-like (Dis-like) and cysteine-rich (Cys-rich) domains following the metalloproteinase
domain. In some PIII SVMPs, two additional C-type lectin-like subunits are covalently linked to the
cysteine-rich domain. Within each one of these SVMP classes, there are several subclasses that vary in
their post-translational processing and quaternary structure [1,6]. SVMPs play key biological roles
for snakes, both as digestive enzymes and as toxicity factors, since they are responsible for local and
systemic hemorrhage, blistering and dermonecrosis, myonecrosis and coagulopathies, in addition to
exerting a pro-inflammatory role [2]. Most of the biological effects of SVMPs depend on their catalytic
activity, particularly on their capacity to hydrolyze extracellular matrix components and coagulation
factors. However, other functions are associated with the non-metalloproteinase domains, such as the
action of disintegrins and disintegrin-like sequences on platelet aggregation [1,2,7,8].
SVMPs constitute a model of evolution and neofunctionalization of multigene families [9].
The evolutionary history of these toxins, which has been characterized by domain loss, gene
duplication, positive selection and neofunctionalization, started with the recruitment of an ADAM
(ADAM 7, ADAM 28 and/or ADAM decysin 1), followed by the loss of C-terminal domains
characteristic of ADAMs, resulting in the formation of P-III SVMPs [10,11]. After that, a duplicated
SVMP PIII gene evolved by positive selection into a PII SVMP via loss of the Cys-rich domain. Then,
PI evolved by disintegrin domain loss, with further neofunctionalization of the metalloproteinase
domain to play diverse biological roles [6,10,11]. PIII SVMPs are present in all advanced snake families,
whereas PI and PII SVMPs occur only in the family Viperidae [2,6]. This accelerated and complex
evolutionary process has generated a great functional diversity in this group of enzymes and the
expression of multiple, structurally-distinct SVMP isoforms in snake venoms [6,12,13].
Many representatives of PII SVMPs undergo a post-translational modification by which the
disintegrin domain is released from the precursor protein [1,6]. However, in two subclasses of PII
SVMPs, i.e., PIIb and PIIc, this proteolytic cleavage does not occur, and the mature proteins are
comprised by the metalloproteinase and the Dis domain held together [6]. In addition, PIIc SVMPs
occur as dimers, whereas PIIb are monomers. Despite the great diversification of SVMPs, to the best of
our knowledge, there are no reports on enzymes with mutations in the canonical zinc-binding motif of
the active site, and all SVMPs described to date are catalytically active.
In the course of the characterization of SVMPs from the venom of the arboreal pit viper
Bothriechis lateralis, a species distributed in Central America [14], a fraction containing internal
sequences characteristic of SVMPs, but being devoid of proteinase and hemorrhagic activities, was
isolated. The characterization of this fraction and the cDNA cloning of a related isoform showed
the presence of modifications in the residues constituting the zinc-binding motif characteristic of the
reprolysin group of metalloproteinases. This study describes the isolation and characterization of these
SVMP variants and discusses some biological implications of their presence in snake venoms.
2. Results
2.1. Purification of SVMP BlatPII
A PII SVMP, hereby named BlatPII, was purified from the venom of B. lateralis by two
chromatographic steps. First, ion-exchange chromatography on diethylaminoethyl (DEAE)-Sepharose
yielded five protein fractions (Figure 1A). Then, Peak III, which showed hemorrhagic activity,
was fractionated by phenyl sepharose chromatography (Figure 1B). Fraction II of the latter
chromatography was devoid of hemorrhagic activity, but had sequences characteristic of SVMPs
by mass spectrometric analysis. When run on SDS-PAGE, it showed bands of 36 kDa and 39 kDa,
under non-reducing and reducing conditions, respectively (Figure 1C), indicating that it is a monomeric
protein containing intramolecular disulfide bond(s). It stained positive in the carbohydrate detection
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test, i.e., it is a glycoprotein (not shown). Reversed-phase HPLC analysis demonstrated that the protein,
apparently homogeneous on SDS-PAGE, can be separated into two peaks (Figure 1D) with molecular
masses of 35,409 ± 248 Da and 36,715 ± 249 Da, estimated by MALDI-TOF mass spectrometry.
Toxins 2016, 8, 292  3 of 20 
 
monomeric  protein  containing  intramolecular  disulfide  bond(s).  It  stained  positive  in  the 
carbohydrate detection  test,  i.e.,  it  is a glycoprotein  (not  shown). Reversed‐phase HPLC analysis 
demonstrated that the protein, apparently homogeneous on SDS‐PAGE, can be separated into two 
peaks  (Figure  1D) with molecular masses of  35,409  ±  248 Da  and  36,715  ±  249 Da,  estimated by 
MALDI‐TOF mass spectrometry. 
 
Figure  1.  Isolation  of  BlatPII  from  B.  lateralis  venom.  Venom was  fractionated  by  ion‐exchange 
chromatography  on  diethylaminoethyl  (DEAE)‐Sepharose  (A);  and  hydrophobic  interaction 
chromatography  on  phenyl  sepharose  (B);  as  described  in  the  Materials  and  Methods.  Arrows 
inserted in (B) correspond to the addition of 100 mL of 0.01 M phosphate buffer, pH 7.8, containing 1 
M NaCl  (a); 100 mL of 0.01 M phosphate buffer, pH 7.8  (b); and 100 mL of deionized water  (c). 
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non‐reducing (Lane 3) conditions. (D) BlatPII was separated into two main peaks by RP‐HPLC. Red 
line  corresponds  to  acetonitrile  gradient  (see  the  text  for  details).  SDS‐PAGE  under  reducing 
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Mass  spectrometry  analysis  and  Edman  N‐terminal  degradation  of  peptides  obtained  by 
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SVMPs  (HEXXHXXGXXH) were  found. One  of  them  (HELGHNLGIHQ)  has  a Gln  instead  of  a 
Figure 1. Isolation of BlatPII from B. lateralis venom. Venom was fractionated by ion-exchange
chromatography on diethylaminoethyl (DEAE)-Sepharose (A); and hydrophobic interaction
chromatography on phenyl sepharose (B); as described in the Materials and Methods. Arrows inserted
in (B) correspond to the addition of 100 mL of 0.01 M phosphate buffer, pH 7.8, containing 1 M NaCl (a);
100 mL of 0.01 M phosphate buffer, pH 7.8 (b); and 100 mL of deionized water (c). Fraction II from the
hydrophobic interaction chr matography is a SVMP devoid of emorrhagic activity and was named
Bl tPII. (C) SDS-PAGE of the purified protein under red cing (Lane 2) a non-reducing (Lane 3)
conditions. (D) BlatPII was separated into two main eaks by RP-HPLC. Red line corresponds to
acetonitrile gradient (see the text for details). SDS-PAGE under re ucing conditions of Peak 1 (Lane 2)
and Peak 2 (Lane 3) is shown in the insert of D). Lane 1 in gels of (C) a d the insert of (D) corresponds
to molecular mass standard (kDa).
2.2. Determination of Internal Peptide Sequences
Mass spectrometry analysis and Edman N-terminal degradation of peptides obtained by digestion
of RP-HPLC Peaks 1 and 2 with different proteinases identified several sequences characteristic
of the metalloproteinase and disintegrin domains of SVMPs (Table 1). Sequences having two
different patterns of substitutions in the canonical sequence of the zinc-binding motif of SVMPs
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(HEXXHXXGXXH) were found. One of them (HELGHNLGIHQ) has a Gln instead of a characteristic
His, whereas the other (HDLGHNLCIDH) has two substitutions, i.e., an Asp instead of Glu and a Cys
replacing a Gly. These sequences were found in peptides having variations in other internal sequences,
hence evidencing the presence of several isoforms within these two basic patterns of substitutions in
the zinc-binding motif (Table 1). Representative high-resolution MS/MS spectra of the above referred
peptides are shown in the Supplementary Material (Figures S1–S5). All fragmentation patterns were
automatically interpreted by PEAKS De Novo software (version 8, Bioinformatics Solutions Inc.,
Waterloo, Canada, 2016). Only sequence results with very high confidence (average local confidence
(ALC) ≥99% and local confidence score for each amino acid ≥98%) were considered. The sequence
RGD, characteristic of many disintegrins, was observed in a few peptides derived from proteins eluted
in the HPLC Peak 2 (Table 1). The high-resolution MS/MS spectrum of one of these peptides is shown
in the Supplementary Material (Figure S6). For this specific peptide, the de novo ALC was 91%, and the
local confidence score for each amino acid ranged from 59% to 99%. All peptides derived from proteins
from HPLC Peaks 1 and 2 identified by automatic de novo sequencing and showing ALC ≥ 99% were
aligned against the BlatPII-c sequence using PepExporer, a similarity-driven tool (Figures S7 and S8).
Considering a minimum identity of 75%, the sequence coverage obtained for BlatPII-c was 22.1% and
49.1%, respectively, for peptides from HPLC Peak 1 and Peak 2.
2.3. Cloning of a P-II SVMP
The PCR amplified a 1458-bp cDNA sequence (Figure 2), with a precursor protein sequence
including a 17-residue N-terminal signal peptide, a pre-pro-domain (residues −18–−190, including the
canonical cysteine switch motif (PKMCGVT)), followed by a mature protein comprising a 206-amino
acid metalloproteinase domain, a short spacer sequence (residues 207–211) and a long PII disintegrin
domain (212–297) containing the characteristic RGD motif. Noteworthy, the metalloproteinase domain
contains the CIM sequence characteristic of the Met-turn of metzincins [4] and a mutated zinc-binding
motif with the sequence HDLGHNLCIDH, instead of the canonical HEXXHXXGXXH. This sequence is
identical to the mutated catalytic site of some of the internal sequences determined in proteins eluted in
Peak 2 of the RP-HPLC separation (Table 1). When comparing the complete sequence of the clone with
the peptide sequences identified in RP-HPLC peaks (Table 1), there were differences in some residues.
Thus, this cDNA-deduced amino acid sequence is likely to correspond to another isoform having
the same substitutions in the canonical catalytic site found in some of the isolated protein isoforms.
The protein coded by the cDNA clone is hereby named BlatPII-c. The BlatPII-c clone presents two Cys
residues, corresponding in the mature protein to residues at positions 217 and 236. The presence of
these Cys residues identifies this domain as a member of the long-chain disintegrin subfamily [13,15]
and has been suggested to underlay the lack of proteolytic processing of the disintegrin domain in
some PII SVMPs. Therefore, the data suggest that BlatPII-c belongs to the subclass PIIb of SVMPs,
i.e., monomeric PII containing metalloproteinase and disintegrin domains in the mature protein [16]
(Figure 2). The sequence of this clone was deposited in GenBank under Accession Number KU885992.
2.4. Proteolytic Activity on Azocasein and Gelatin
Proteolytic activity on these two substrates was tested with the fraction BlatPII, which contains
isoforms that can be separated only by RP-HPLC. Since the solvents used for this separation denature
the enzymes, it was not possible to assess the proteolytic activity of the RP-HPLC peaks separately.
Under the experimental conditions used, BlatPII did not show proteolytic activity on the two substrates
tested. In contrast, both BaP1 and BlatH1 SVMPs, which are active proteinases, hydrolyzed azocasein
and gelatin (Figure 3).
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Table 1. Amino acid sequence of peptides obtained by digestion with trypsin, chymotrypsin or Glu-C endoproteinases from Peak 1 and Peak 2 of RP-HPLC,
as determined by mass spectrometry (MALDI-TOF-TOF or nESI-MS/MS) or Edman N-terminal sequencing.
Peptide Sequence HPLC Peak m/z z Confidence a Error b (ppm) Method c Domain
YIELVIVADHR 1 1327.8 1 MV 47.4 MALDI/DE NOVO metalloproteinase
NLTPEEQRY 1 1149.6 1 MV 40.0 MALDI/DE NOVO metalloproteinase
SRYHFVANR 1 1149.6 1 MV 7.8 MALDI/DE NOVO metalloproteinase
YHFVANR 1 - MV - EDMAN metalloproteinase
MAHELGHNLGIHQDR 1 - - MV - EDMAN metalloproteinase
MAHELGHNLGIHQDR 1 1727.8 1 MV 22.5 MALDI/DE NOVO metalloproteinase
MAHELGHNLGLHQDR 1 576.6180 3 99 0.2 nESI/DE NOVO metalloproteinase
DSCSCGSNSCIMSATVSNEPSSR 1 2493.0 1 MV 10.0 MALDI/DE NOVO metalloproteinase
CIDNEPLR 1 1016.5 1 MV 16.7 MALDI/DE NOVO metalloproteinase
NEPLRTDIVSPPFCGNYYPE * 1 2368.3 1 MV 88.2 MALDI/DE NOVO metalloproteinase/disintegrin
LTTGSQCAEGLCCDQCR 1 2015.9 1 MV 47.6 MALDI/DE NOVO disintegrin
FEGLCCDQCR 1 1344.4 1 MV 84.0 MALDI/DE NOVO disintegrin
RTDIVSPPF ** 1 1031.6 1 MV 46.5 MALDI/DE NOVO disintegrin
YIELVIVADHR 2 1327.8 1 MV 47.4 MALDI/DE NOVO metalloproteinase
VTLSADDTLDLFGTWR 2 - MV - EDMAN metalloproteinase
VALIGLEIWSSGELSK 2 1702.0 1 MV 34.0 MALDI/DE NOVO metalloproteinase
YHFVANR 2 906.5 1 MV 46.3 MALDI/DE NOVO metalloproteinase
MAHDLGHNLCIDHDR 2 1803.9 1 MV 54.8 MALDI/DE NOVO metalloproteinase
MAHDLGHNLCLDHDR 2 902.4039 2 99 −0.4 nESI/DE NOVO metalloproteinase
MAHDLGHNLCLDHDDR 2 959.9163 2 99 −1.5 nESI/DE NOVO metalloproteinase
MAHELGHNLGLHQDDR 2 614.9611 3 99 1.2 nESI/DE NOVO metalloproteinase
MAHELGHNLGLHQDR 2 864.4214 2 99 −2.1 nESI/DE NOVO metalloproteinase
NKPSETDIVSPPVCGNYY ** 2 2040.1 1 MV 79.4 MALDI/DE NOVO metalloproteinase/disintegrin
CNGISAGCPRNPF ** 2 1449.7 1 MV 44.1 MALDI/DE NOVO disintegrin
RARGDDVNDYCNGISAGCPRNPFH * 2 2748.4 1 MV 68.7 MALDI/DE NOVO disintegrin
ARGDDVNDYCNGISAGCPR 2 2097.1 1 MV 101.5 MALDI/DE NOVO disintegrin
ARGDDVDDYCDGLDAGCPR 2 709.6204 3 91 −1.7 nESI/DE NOVO disintegrin
AATCKLTTGSQCADGLCCDQCKFMRE * 2 3068.5 1 MV 71.0 MALDI/DE NOVO disintegrin
a Confidence: MALDI/DE NOVO and EDMAN (MV, manual validation); nESI/DE NOVO (PEAKS 8 De Novo average local confidence); b Error: error of the precursor ion
(in ppm) relative to the proposed sequence; c Method: MALDI/DE NOVO: MALDI-TOF-TOF and manual de novo sequencing; EDMAN: N-terminal sequencing; nESI/DE NOVO:
nLC-nanoelectrospray MS/MS and automatic de novo sequencing using PEAKS 8 software; * peptides generated by Glu-C endoproteinase digestion; ** peptides generated by
chymotrypsin digestion. Peptides without asterisks were obtained following trypsin digestion. All cysteines are carboxamidomethylated. Sequences colored in red correspond to the
mutated catalytic site.
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sequence RGD  in  the disintegrin domain. Cysteine residues proposed  to be related  to  the  lack of 
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2.4. Proteolytic Activity on Azocasein and Gelatin 
Figure 2. cDNA sequence and deduced amino acid sequence of BlatPII-c. The deduced amino acid
sequence of the mature protein is depicted in bold letters and is preceded by the pro-domain, which
contains the sequence PKMCGVT characteristic of the Cys switch (highlighted in green). Sequences
corresponding to signal peptide, pro-domain, metalloproteinase domain, spacer region and the
disintegrin domain are indicated. The sequences corresponding to the mutated zinc-binding motif
and the sequence CIM (Cys-Ile-Met) of the Met-turn are highlighted in yellow, as well as the sequence
RGD in the disintegrin domain. Cysteine residues proposed to be related to the lack of proteolytic
processing of the disintegrin from the metalloproteinase domain are labeled with asterisks. Primers
used to PCR-amplify the cDNA clone and the C-terminal amino acid sequence gathered by MS/MS
analysis of a tryptic peptide are shown.
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fluorescent  commercial  kit  (EnzCheck®  protocol  Gelatinase/Collagenase  Assay  Kit,  Molecular 
Probes, Life Technologies, Eugene, OR, USA). One‐point‐six micrograms of BlatPII were incubated 
with 20 μg of the fluorescent gelatin; equimolar quantities of BaP1 and BlatH1 were used as positive 
controls; samples were incubated at room temperature for 6 h. Fluorescence intensity was measured 
in the BioTek Synergy HT microplate reader using the absorption filter at 495 nm and the emission 
filter at 515 nm. * p < 0.05 when compared with BaP1 and BlatH1. In (A,B), the signal of BlatPII was 
Figure 3. Evaluation of the proteolytic activity of Blat II and other SVMPs on azocasein and gelatin.
(A) BlatPII (5.5 µM) was incubated with azocasein (see the Materials and Methods for details).
For comparison, an equimolar concentration of PI SVMP BaP1, from the venom of Bothrops asper,
and of the hemorrhagic PII SVMP BlatH1, from the venom of Bothriechis lateralis, were also tested.
PBS was used as a negative control; (B) Quantification of the gelatinolytic activity of the SVMP by a
fluorescent comm rcial kit (EnzCheck® protocol Gelatinase/Collagenase Ass y Kit, Molecular Probes,
Life Technologies, Eugene, OR, USA). One-point-six micrograms of BlatPII were incubated with 20 µg
of the fluorescent gelatin; equimolar quantities of BaP1 and BlatH1 were used as positive controls;
samples were incubated at room temperature for 6 h. Fluorescence intensity was measured in the
BioTek Synergy HT microplate reader using the absorption filter at 495 nm and the emission filter
at 515 nm. * p < 0.05 when compared with BaP1 and BlatH1. In (A,B), the signal of BlatPII was
not significantly different when compared to the controls without enzyme (p > 0.05); (C) Gelatin
zymography: 2.5 µg of BlatPII (Lane 2) and 2.5 µg of BlatH1 (Lane 3) were separated on SDS-PAGE
under non-reducing conditions. Lane 1 corresponds to molecular mass standards. The dark band
observed in Lane 2 corresponds to BlatPII, whose migration in SDS-PAGE-gelatin gels is delayed as
compared to SDS-PAGE gels without gelatin.
2.5. Hemorrhagic, Edema-Forming, Coagulant and Platelet Aggregation Inhibitory Activities
BlatPII did not exert local hemorrhagic activity when injected in the skin of mice at a dose of
100 µg, nor did it show coagulant activity on human plasma. Likewise, the protein did not induce
pulmonary hemorrhage after i.v. injection of 100 µg in mice. On the other hand, BlatPII demonstrated
a low edema-forming activity (Figure 4), and inhibited ADP- and collagen-mediated aggregation of
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human platelets in PRP, with estimated IC50s of 0.25 and 0.33 µM, respectively (Figure 5A,B). In the
case of the peaks obtained by RP-HPLC separation, Peak 1 did not induce the inhibition of platelet
aggregation, while Peak 2 inhibited platelet aggregation using ADP and collagen as the agonists
(Figure 5C).
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Figure 4. Edema-forming activity of BlatPII. Groups of four CD-1 mice were injected subcutaneously
in the right footpad with 5 µg of BlatPII, in a volume of 50 µL PBS. Controls were injected with 50 µL
PBS only. The paw thickness was measured using a low pressure spring caliper, as a quantitative index
of edema, b fore injection and at 30, 60, 180 and 360 min after injection. Edema was calculated as
the percentage of increase in the paw thickn ss of the right foot injected with SVMP s compared to
the left foot; in parallel, 5 µg of BlatH1 were used as a positive control. BlatH1 induced significantly
higher (p < 0.05) edema than BlatPII at all time intervals, whereas BlatPII induced a significant edema,
as compared to the control, only at 60 and 180 min (* p < 0.05).
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Figure 5. Inhibition of platelet aggregation by BlatPII and RP-HPLC Peaks 1 and 2. Various
concentrations of BlatPII were tested using ADP (A) or collagen (B) as agonists. (C) Inhibition of
platelet aggregation by HPLC Peak 1 and Peak 2. Results presented correspond to one experiment
representative of three different independent experiments.
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2.6. Three-Dimensional Model of the Active Site of BlatPII-c
As described above, the clone codes for the sequence HDLGHNLCIDH instead of the characteristic
canonical site HEXXHXXGXXH at the enzyme active site. Three-dimensional structures, based on
homology models, were generated using the Modeller method available in the Accelrys Discovery
Studio 3.5 software [17]. The vascular apoptosis-inducing protein 1 (VAP-1) (PDB Code 2ERQ) was
used as a template. After aligning the generated model of the BlatPII-c with the VAP-1 crystal structure,
it was shown that the substitution of Glu for Asp causes an increase in the distance between residue
Asp335 and the water molecule (4.203 Å), both of which play a key role in the hydrolysis of the peptide
bond. In the case of VAP-1, a PIII SVMP from the venom of Crotalus atrox, which has the characteristic
active site with Glu, the distance between the water molecule and Glu is 2.691 Å (Figure 6). A PIII
SVMP (VAP-1) was used as a model, because no PII SVMP has been crystallized, and the sequence
identity percentage between these toxins is acceptable (55%) for the modeling program.
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Figure 6. 3D model of the active site HDLGHNLCIDH. Using the Discovery Studio Program Version
3.5.0.12158 (Accelrys Software Inc, San Diego, CA, USA), a 3D model of the active site of BlatPII was
generated (A). Determination of distances in the predicted model was made using the coordinates of
the zinc atom and the water molecule from the crystallographic structure of VAP-1 from venom of
Crotalus atrox (B).
3. Discussion
In contrast to the SVMPs described so far, the PII SVMP homologues described in the present study
have the peculiarity of being devoid of proteinase activity. To the best of our knowledge, this constitutes
the first case of a snake venom protein having a SVMP structural scaffold, but ing devoid of
proteolytic activity. Mass spectrometric and molecular analyses of the isoforms f BlatPII underscore
the presence of mutations in the c nonical sequence of the zinc-binding mo if char cteristic of the
active site of SVMPs. In the canonical equence (HEXXHXXGXXH), the catalytic zinc is coordinated
by the three His residu s, and a water molecule plays the role of a fourth ligand and is clamped
between the catalytic Glu of the motif and the metal, forming a trigonal pyramidal coordin tion
sphere aroun the zinc [4]. In the catalytic process, the water olecule is added t the peptidic bond
by a nucleophilic attack, in which the carbonyl group of the scissile peptide bond is polarized by
the active site zinc. In such a mechanism, the zinc-bound water molecule ediates betwe n this
carbonyl group and the atalytic Glu residue, giving rise to the acquisition of nucleophilicity by the
water molecule, n cessary for attacki g the carbonyl carbon of the scissile peptide bond, resulting
in a tetra-coordin te transiti n state. The catalytic Glu then presumably serves as a proton huttle
to the cleavage products [4,18,19]. Th s, it is likely that the substitutions of these highly-conserved
catalytic residues occ rrin i the isoforms of BlatPII drastically affect one or more steps in this catalytic
process. The esence of catalytically-in ctive SVMP homologues in snake v noms need to be further
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investigated since the isolation of SVMPs is usually followed by testing proteinase or toxic activities
of the chromatographic fractions; this approach does not detect catalytically-inactive variants. It is
therefore recommended that the search for this type of inactive SVMP homologues is based on either
immunological detection of components cross-reacting with SVMPs or on the proteomic identification
of these variants, as performed in our study.
In contrast to SVMPs, where no examples of enzymatically-inactive variants have been described
before, mutations in the catalytic site have been reported in the case of the other branch of the
reprolysin group of metalloproteinases, i.e., the ADAMs [1,20,21]. Some ADAMs have completely
lost the sequence of the zinc-binding motif [1,21–24]. In other cases, such as ADAMDEC-1 [20] and
ADAM-7 [21,25], substitutions in this canonical motif have been described, with variable impact on
the proteolytic activity of these proteins. On the other hand, the detection of several mutated isoforms
of BlatPII and the presence of variations in the internal sequences determined highlight the existence
of several isoforms in this venom within the two basic mutated patterns of the zinc-binding motif.
Two basic patterns of substitutions in the canonical sequence of the zinc-binding motif were
found in our study. In one case, an Asp substitutes the Glu and a Cys substitutes a Gly, whereas in
the other, a Gln substitutes the third His in the canonical sequence. It is therefore proposed that these
substitutions drastically affect the catalytic machinery in these PII SVMP homologues. A 3D modeling
of the active site, using the sequence of BlatPII-c, showed that the substitution of Glu for Asp causes
an increase of the distance between the Asp335 residue and the water molecule, as compared to the
distance between Glu335 and water in a catalytically-active variant. The increment of this distance
may affect the activation of the water molecule, thus precluding the nucleophilic attack of the peptide
bond. On the other hand, the substitution of a Gly by Cys might also bear structural consequences that
affect the catalytic machinery. The elucidation of the 3D structure of BlatPII-c will certainly provide an
explanation for the described effect in proteolytic activity.
The lack of hemorrhagic and coagulant activities in BlatPII is probably related to the loss of
enzymatic activity, since these effects have been associated with proteolysis in catalytically-active
SVMPs. The observation that BlatPII induces mild edema is compatible with a study that described
edema-forming activity of a fragment constituted by the Dis-like and Cys-rich domains [26].
HPLC peak 2 inhibits platelet aggregation induced by ADP and collagen, and as expected, sequences
found in HPLC Peak 2 present the characteristic RGD motif in the disintegrin domain. Since this
sequence is associated with the ability of many disintegrins to bind αIIBβ3 integrin in the platelet
membrane, causing inhibition of aggregation [27–29], it is suggested that it is responsible for the effect
observed in platelets.
The existence of catalytically-inactive PII SVMP homologues in the venom of B. lateralis is
intriguing from the adaptive standpoint, since most of the described biological roles of SVMPs,
associated with both prey immobilization and digestion, are dependent on the proteolytic degradation
of diverse substrates, usually extracellular matrix components or plasma proteins [2]. BlatPII isoforms
are devoid of hemorrhagic and coagulant effects, in agreement with their lack of proteinase activity.
The only biological effects shown by BlatPII were a mild edema-forming effect and inhibition of platelet
aggregation, which may be due to the presence of RGD in the disintegrin domain and may play a
role in the overall toxicity of the venom by affecting this aspect of hemostasis, although this requires
experimental demonstration. Alternatively, the presence of BlatPII in the venom may reveal a neutral
evolutionary process by which these catalytically-inactive homologues are expressed in the venom
gland without playing a significant trophic role. Many components have been described in snake
venoms that have not been shown to play a biological role. Nevertheless, it would be relevant to
explore the possible toxicity of these isoforms by assessing a wider set of effects and also by studying
their toxicity in prey other than mice, since adult B. lateralis also feeds on birds and bats in addition to
rodents [14].
In the wider context of hydrolytic enzymes, examples of catalytically-inactive homologues of
phospholipases A2 (PLA2) and of serine proteinases have been described in snake venoms. In the
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case of PLA2 homologues, substitutions of key residues in the catalytic machinery have resulted in
the loss of enzymatic activity. However, many catalytically-inactive PLA2 homologues exert toxic
effects, such as myotoxicity and pro-inflammatory activities, owing to the appearance of ‘toxic sites’
in some regions of the surface of these molecules [30]. Likewise, serine proteinase homologues have
been reported, which are characterized by substitutions in the catalytic triad His, Asp, Ser [31,32]. In a
serine proteinase isolated from the venom of Trimeresurus jerdonii, the replacement of His-43 by Arg-43
at the catalytic triad has been associated with the loss of proteolytic activity [32].
In conclusion, cDNA encoding for a PII SVMP and several isoforms of PII SVMP homologues with
a mutated catalytic site occur in the venom of the arboreal viperid snake B. lateralis, which contains a
high percentage of SVMPs (55.1%) [33]. Such mutations in the canonical sequence of the zinc-binding
motif of these enzymes are likely to be responsible for the lack of enzymatic activity observed. To
the best of our knowledge, this is the first case of catalytically-inactive SVMP homologues described
in snake venoms. The possible biological role, if any, of these SVMP variants remains unknown,
although one of them is able to inhibit ADP- and collagen-induced platelet aggregation in vitro. These
components expand the wide set of SVMP variants in viperid snake venoms. The search for other
enzymatically-inactive SVMP homologues in venoms is a relevant task in order to ascertain how
frequent they are and to discover new possible biological roles for this group of venom components.
4. Materials and Methods
4.1. Venom and Toxins
A pool of venom obtained from at least 20 adult specimens of B. lateralis collected in various
locations of Costa Rica, and maintained at the Serpentarium of Instituto Clodomiro Picado, was used.
Venom was lyophilized and stored at −20 ◦C. Venom solutions were prepared immediately before
each experiment. In some experiments, BlatH1, a PII SVMP isolated from the venom of B. lateralis [34],
and BaP1, a PI SVMP from the venom of Bothrops asper [35], were used for comparative purposes.
4.2. Purification of SVMP
One hundred milligrams of B. lateralis venom were dissolved in 5 mL of 0.01 M phosphate buffer,
pH 7.8, and centrifuged at 500× g for 10 min. The supernatant was loaded onto a DEAE sepharose
column (column 10 cm in length × 2 cm internal diameter) previously equilibrated with the same
buffer. After eluting the unbound material, a linear NaCl gradient (0–0.4 M) was applied, and fractions
were collected at a flow rate of 0.3 mL/min. The fraction containing SVMPs, identified on the basis
of hemorrhagic activity in mice, was then adjusted to 1 M NaCl and applied to a phenyl sepharose
hydrophobic interaction column (6 cm × 1.5 cm i.d.). Unbound proteins were eluted with 100 mL
of 0.01 M phosphate buffer, pH 7.8, containing 1 M NaCl. Then, 100 mL of 0.01 M phosphate buffer,
pH 7.8, were applied, and finally, the chromatographic separation was finished by the addition of
100 mL of deionized water. The eluted fractions were analyzed by SDS-PAGE, hemorrhagic activity
and mass spectrometry analysis of tryptic peptides. A peak of 39 kDa devoid of hemorrhagic activity,
but showing amino acid sequences corresponding to SVMPs, was isolated after the application of
100 mL of 0.01 M phosphate buffer, pH 7.8, and was further characterized in this study; it was named
BlatPII. The peak obtained after the application of water has been previously characterized as a dimeric
PII hemorrhagic SVMP, known as BlatH1 [34]. Homogeneity and molecular mass were determined by
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing and non-reducing conditions,
using 12% polyacrylamide gels [36].
4.3. HPLC Separation of Isoforms
One hundred micrograms of BlatPII were loaded on a Thermo AQUASIL C4 column
(150 mm × 4.6 mm i.d.), and the reversed-phase HPLC fractionation was made on an Agilent
1200 instrument (Agilent Technologies, Santa Clara, CA, USA) at a flow of 0.5 mL/min, with detection
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set at 215 nm. The solvent system was 0.1% trifluoroacetic acid in H2O (Solvent A) and 0.1%
trifluoroacetic acid in acetonitrile (Solvent B). The gradient program began with 0% Solvent B for 5 min
and was then ramped to 70% Solvent B at 300 min, followed by 70% Solvent B for 5 min.
4.4. Mass Spectrometry Analyses
4.4.1. MALDI-TOF/TOF
Mass determination of the whole protein was performed by mixing 0.5 µL of saturated sinapinic
acid (in 50% acetonitrile, 0.1% trifluoroacetic acid) and 0.5 µL of sample, which were spotted
onto an OptiTOF-384 plate, dried and analyzed in positive linear mode on an Applied Biosystems
4800-Plus MALDI-TOF/TOF instrument (Applied Biosystems, Framingham, MA, USA). Mass spectra
were acquired with delayed extraction in the m/z range of 20,000–130,000, at a laser intensity of
4200 and 500 shots per spectrum. Protein identification and amino acid sequencing of peptides
obtained by digestion with trypsin, chymotrypsin or endoproteinase Glu-C were carried out by CID
tandem mass spectrometry. Protein bands were excised from Coomassie Blue R-250-stained gels
(12% polyacrylamide) following SDS-PAGE run under either reducing or non-reducing conditions and
were reduced with dithiothreitol, alkylated with iodoacetamide and digested with sequencing-grade
bovine trypsin (Sigma-Aldrich Co, St. Louis MO, USA), chymotrypsin (GBiosciences, St. Louis, MO,
USA) or endoproteinase Glu-C (V8 protease) (GBiosciences, St. Louis, MO, USA), on an automated
processor (ProGest, Digilab, Marlborough, MA, USA) overnight at 37 ◦C, according to the instructions
of the manufacturer. The peptide mixtures were then analyzed by MALDI-TOF-TOF. Mixtures of
0.5 µL of sample and 0.5 µL of saturated α-cyano-4-hydroxycinnamic acid (in 50% acetonitrile, 0.1%
trifluoroacetic acid) were spotted, dried and analyzed in positive reflector mode. Spectra were
acquired using a laser intensity of 3000 and 1625 shots per spectrum, after external MS and MS/MS
calibration with CalMix-5 standards (ABSciex, Framingham, MA, USA) spotted on the same plate.
Up to 10 precursor peaks were selected from each MS spectrum for automated collision-induced
dissociation MS/MS spectra acquisition at 2 kV (500 shots/spectrum, laser intensity of 3000).
The spectra were analyzed using ProteinPilot v.4.0.8 and the Paragon® algorithm (ABSciex) against the
UniProt/SwissProt database (Serpentes; downloaded 12 January 2016) for protein identification at
a confidence level of 99%. Subsequently, sequences were manually inspected to confirm amino acid
sequences de novo.
4.4.2. nLC-MS/MS
RP-HPLC Peaks 1 and 2 were dissolved in 0.4 M ammonium bicarbonate/8 M urea, reduced in
10 mM dithiothreitol at 37◦C for 3 h, alkylated in 25 mM of iodoacetamide, followed by final quenching
step in 4.5 mM DTT. The last two steps were performed at room temperature, in the dark, for 15 min
each. After diluting the urea to 1 M, trypsin (Promega, Madison, WI, USA) was added (enzyme to
substrate ratio 1:50 w/w) and the hydrolysis proceeded for 18 h at 37◦C. Trifluoroacetic acid was then
added to a final concentration of 1% (v/v), followed by sample desalting on Poros R2 microcolumns.
Peptides were completely dried in a vacuum centrifuge, followed by re-suspension with 1% formic
acid in water. Peptide quantitation (2 µL aliquots) was based on the UV absorbance at 280 nm
on a NanoDrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA, USA) (1 Absorbance
unit = 1 mg/mL, considering 1 cm path length). Peptides (~1 µg) were submitted to a reversed
phase nanochromatography (Ultimate 3000 system, Thermo Scientific Dionex, Sunnyvale, CA, USA)
hyphenated to a quadrupole Orbitrap mass spectrometer (Q Exactive Plus, Thermo Scientific, Waltham,
MA, USA). For desalting and concentration, samples were first loaded at 2 µL/min onto a home-made
capillary guard column (2 cm × 100 µm i.d.) packed with 5 µm, 200 Å Magic C18 AQ matrix (Michrom
Bioresources, Auburn, CA, USA). Peptide fractionation was performed at 200 nL/min on an analytical
column (30 cm × 75 µm i.d.) with a laser pulled tip (~5 µm), packed with 1.9 µm ReproSil-Pur 120
C18-AQ (Dr. Maisch). The following mobile phases were used: (A) 0.1% formic acid in water; (B) 0.1%
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formic acid in acetonitrile. Peptides were eluted with a gradient of 2%–40% B over 162 min, which
was increased to 80% in 4 min, followed by a washing step at this concentration for 2 min before
column re-equilibration.
Using data-dependent acquisition, up to 12 most intense precursor ions in each survey scan
(excluding singly-charged ions and ions with unassigned charge states) were selected for higher energy
collisional dissociation (HCD) fragmentation with 30% normalized collision energy. The following
settings were used: (a) full MS (profile mode): 70,000 resolution (FWHM at m/z 200), Automatic
Gain Control (AUC) AGC target 1 × 106, maximum injection time 100 ms, scan range 300–1500 m/z;
(b) dd-MS/MS (centroid mode): 17,500 resolution, AGC target 5 × 104, maximum injection time 50 ms,
isolation window 2.0 m/z (with 0.5 m/z offset), dynamic exclusion 60 s. The spray voltage was set
to 1.9 kV with no sheath or auxiliary gas flow and with a capillary temperature of 250 ◦C. Data were
acquired in technical triplicates using the Xcalibur software (Version 3.0.63, Thermo Fisher Scientific,
Waltham, MA, USA). To avoid cross-contamination, two blank injections were run before the analysis
of each biological replicate. The mass spectrometer was externally calibrated using a calibration
mixture that was composed of caffeine, peptide MRFA and Ultramark 1621, as recommended by the
instrument manufacturer.
PEAKS (version 8, Bioinformatics Solutions Inc., Waterloo, KW, Canada, 2016) was used
for de novo sequencing analysis, using the following parameters: fixed cysteine modification
(carbamidomethylation); 10 ppm peptide mass error tolerance; 0.02 Da fragment mass tolerance.
Only de novo sequences showing ≥99% ALC (average of local confidence) were exported and
submitted to sequence alignment against the mature BlatPII-c clone sequence using the algorithm
PepExplorer [37]. The following parameters were used in the similarity-driven analysis: 75% minimum
identity, minimum of 6 residues per peptide, substitution matrix PAM30MS.
4.5. Determination of Internal Peptide Sequences by Edman Degradation
The fractions obtained by reversed-phase HPLC were dried and reconstituted in 20 µL of
0.4 M NH4HCO3, 8 M urea. Then, 5 µL of 100 mM dithiothreitol were added, and the solution
was incubated for 3 h at 37 ◦C. After that, 400 mM of iodoacetamide were added and incubated at
room temperature for 15 min, protected from light. Then, 130 µL of deionized water were added, and
digestion was performed with 2 µg trypsin (Sigma-Aldrich Co, St. Louis, MO, USA), overnight at
37 ◦C. The reaction was stopped with 20 µL of 1% (v/v) trifluoroacetic acid. Peptides were separated
by reversed-phase HPLC on an Agilent 1200 instrument (Agilent Technologies, Santa Clara, CA, USA)
in a Thermo AQUASIL C18 column (4.6 × 150 mm) at a flow of 0.5 mL/min, with detection at 215 nm.
The solvent system was 0.1% trifluoroacetic acid in H2O (Solvent A) and 0.1% trifluoroacetic acid in
acetonitrile (Solvent B). The gradient program started with 5% Solvent B for 5 min and was then raised
to 75% Solvent B at 50 min, and 75% Solvent B was maintained for 5 min. N-terminal sequences of
isolated peptides were determined on a Shimadzu Biotech PPSQ 33A instrument according to the
manufacturer´s instruction. These tryptic peptides were also used for MALDI-TOF/TOF MS analysis.
4.6. Detection of Carbohydrates
Two-point-five micrograms of purified SVMP were separated by 12% SDS-PAGE under reducing
and non-reducing conditions. The gel was stained using a Pro-Q Emerald 300 Glycoprotein Kit
(Molecular Probes, Eugene, OR, USA), as described by the manufacturer.
4.7. PCR Amplification of SVMPs cDNA
An adult specimen of B. lateralis, kept at the Serpentarium of Instituto Clodomiro Picado,
was sacrificed 3 days after venom extraction, and its venom glands were dissected out for
total RNA isolation. After homogenization of the venom glands, the total RNA was extracted
using the RNeasy Mini Kit (Qiagen, Hilden, Germany), following the manufacturer´s instructions.
The first strand of cDNA was reverse-transcribed using the RevertAid H Minus First Strand cDNA
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Synthesis kit, according to the manufacturer's (ThermoScientific, Waltham, MA, USA) protocol,
using the Qt-primer 5′-CCAGTGAGCAGAGTGACGAGGACTCGAGCTCAAGC(T)17-3′. cDNAs
coding for PII SVMP sequences were amplified by PCR using the following primers: Forward (Fw)
primer 5′-ATGATCCCAGTTCTCTTGGTAACTATATGCTTAGC-3′ (corresponding to a conserved
sequence in the pro-peptide of a metalloproteinase precursor; Figure 2), and reverse (Rev) primer,
5′-AGCCATTACTGGGACAGTCAGCAG-3′, coding for the C-terminal amino acid sequence of BlatPII,
obtained by mass spectrometry analysis (Figure 2). The PCR program was as follows: initial
denaturation step (94 ◦C for 2 min), 35 cycles of denaturation (94 ◦C for 45 s), annealing (55 ◦C
for 45 s), extension (72 ◦C for 120 s) and final extension (72 ◦C for 10 min). The PCR products were
separated by 1% agarose electrophoresis, and the fragments with the expected molecular mass were
purified using Illustra GFXTM PCR DNA and Gel Band Purification Kit (GE Healthcare, Life Sciences,
Uppsala, Sweden). The purified sequences were cloned in a pGEM-T vector (Promega, Madison, WI,
USA), which were used to transform Escherichia coli DH5α cells (Novagen, Darmstadt, Germany) by
using an Eppendorf 2510 electroporator following the manufacturer's instructions. Positive clones,
selected by growing the transformed cells in LB (Luria-Bertani medium) (Thermo Fisher Scientific,
Waltham, MA, USA) broth containing 10 µg/mL of ampicillin, were confirmed by PCR-amplification
using M13 primers of the pGEM-T vector. The inserts of positive clones were isolated using kit Wizard
(Promega) and sequenced on an Applied Biosystems Model 377 DNA sequencer.
4.8. Proteolytic Activity on Azocasein
The proteinase activity of the SVMP on azocasein was assessed according to [38]. For comparative
purposes, the PI SVMP BaP1 and the dimeric PII SVMP BlatH1 were used.
4.9. Proteolytic Activity on Gelatin
Proteolytic activity on gelatin was assessed by two methods: gelatin zymography and using a
fluorescent commercial kit (EnzCheck® protocol Gelatinase/Collagenase Assay Kit, Molecular Probes,
Life Technologies, Eugene, OR, USA). For the zymography, the method described by Herron et al. [39],
as modified by Rucavado et al. [40], was used. Briefly, 2.5 µg of the SVMP were separated on a
10% SDS-PAGE containing 0.5 mg/mL of Type A gelatin (Sigma Chemical Co., St Louis, MO, USA).
The same amount of BlatH1 was included as a positive control. After electrophoresis, gels were
incubated with zymography substrate buffer overnight at 37 ◦C. Then, the gel was stained with 0.5%
Coomassie Blue R-250 in acetic acid:isopropyl alcohol:water (1:3:6) and destained with distilled water to
visualize gelatinolytic bands. In order to quantify the gelatinolytic activity of the SVMP, the commercial
kit EnzCheck® was used following the manufacturer’s instructions. Various concentrations of the
SVMP, dissolved in 100 µL of reaction buffer, were incubated with 20 µg of the fluorescent gelatin
substrate in a 96-well microplate. Samples were incubated at room temperature for 6 h and protected
from light. Samples were analyzed in triplicate; a reagent blank was included. BlatH1 and BaP1
were included as positive controls. Fluorescence intensity was measured in the BioTek Synergy HT
microplate reader using the absorption filter at 495 nm and the emission filter at 515 nm.
4.10. Local and Systemic Hemorrhagic Activities
Local hemorrhagic activity was determined by the mouse skin test [41]. Groups of four CD-1
mice (18–20 g) were intradermally (i.d.) injected in the ventral abdominal region with different doses
of B. lateralis SVMP, dissolved in 100 µL of PBS. After 2 h, animals were sacrificed by CO2 inhalation.
The presence of hemorrhagic areas in the inner side of the skin was determined. The experimental
protocols involving the use of animals in this study were approved by the Institutional Committee
for the Care and Use of Laboratory Animals (CICUA) of the University of Costa Rica. Systemic
hemorrhagic activity was tested as described by Escalante et al. [42]. Groups of four CD-1 mice
were intravenously (i.v.) injected, in the tail vein, with various doses of the SVMP, dissolved in
100 µL PBS. After one hour, mice were sacrificed by an overdose of a ketamine/xylazine mixture.
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The thoracic cavity was opened, and the presence of hemorrhagic spots was assessed by macroscopic
observation of the lungs. Lungs of injected animals were dissected out and fixed in formalin solution
for processing and embedding in paraffin. Then, sections were stained with hematoxylin-eosin for
microscopic observation.
4.11. Edema-Forming Activity
The edema-forming activity was assessed according to the method of Lomonte et al. [43].
Groups of four CD-1 mice were injected subcutaneously (s.c.) in the right footpad with 5 µg of
SVMP, dissolved in 50 µL PBS. In other mice, the SVMP BlatH1 was used as a positive control. Control
mice were injected with PBS under otherwise identical conditions. The paw thickness was measured
using a low pressure spring caliper before injection and at 0, 30, 60, 180 and 360 min after injection.
Edema was calculated as the percentage of increase in the paw thickness of the right foot injected with
SVMP as compared to the thickness before injection.
4.12. Coagulant Activity
Coagulant activity was determined as described by [44], with the following modifications: various
doses of SVMP, dissolved in 25 µL PBS, were added to 0.25 mL of citrated human plasma, previously
incubated for 5 min at 37 ◦C. Coagulant activity was monitored for 15 min at 37 ◦C. PBS was used as a
negative control.
4.13. Platelet Aggregation Inhibitory Activity
Platelet-rich plasma (PRP) was obtained from adult healthy human volunteers, as described [45].
Two hundred twenty five microliters of PRP were pre-warmed at 37 ◦C for 5 min. The SVMP, dissolved
in 25 µL of sterile saline solution, was added to PRP, and the mixture incubated for 5 min. After that,
either ADP (20 µM final concentration) or collagen (10 µg/mL final concentration) (Helena Laboratories,
Beaumont, TX, USA) was added to the PRP-SVMP mixture, and platelet aggregation was recorded for
5 min using an AggRAM analyzer (Helena Laboratories, Beaumont, Texas, TX, USA) at a constant spin
rate of 600 rpm. Platelet aggregation was expressed as the percentage of transmittance, considering
100% response the aggregation induced by ADP or collagen alone.
4.14. Statistical Analysis
Significant differences between the mean values of experimental groups were assessed by one-way
ANOVA, and a Tukey post-test was used in order to compare all pairs of means. Values of p lower
than 0.05 were considered significant.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6651/8/10/292/s1,
Figure S1: High-resolution fragmentation spectrum of the m/z 576.6180 ion (z = 3; precursor error 0.2 ppm)
from HPLC Peak 1 obtained on a QExactive Plus instrument (Thermo Scientific, Waltham, MA, USA) (A); the
peptide sequence was interpreted by the PEAKS 8 de novo sequencing software. The average local confidence was
set to 99%, and the local confidence score for each amino acid (i.e., “the likelihood of each amino acid assignment”)
was ≥98%. (B) Ion table showing the calculated mass of possible fragment ions. All fragment ions matching
a peak within the mass error tolerance were colored blue (b-ion series) or red (y ion series). The lower graph
shows the mass error distribution of all matched fragment ions (represented by blue and red dots); Figure S2:
High-resolution fragmentation spectrum of the m/z 614.9611 ion (z = 3; precursor error 1.2 ppm) from HPLC Peak
2 obtained on a QExactive Plus instrument (A). The peptide sequence was interpreted by the PEAKS 8 de novo
sequencing software. The average local confidence was set to 99%, and the local confidence score for each amino
acid (i.e., “the likelihood of each amino acid assignment”) was ≥98%. (B) Ion table showing the calculated mass
of possible fragment ions. All fragment ions matching a peak within the mass error tolerance were colored blue
(b-ion series) or red (y ion series). The lower graph shows mass error distribution of all matched fragment ions
(represented by blue and red dots); Figure S3: High-resolution fragmentation spectrum of the m/z 864.4214 ion
(z = 2; precursor error −2.1 ppm) from HPLC Peak 2 obtained on a QExactive Plus instrument (A). The peptide
sequence was interpreted by the PEAKS 8 de novo sequencing software. The average local confidence was set to
99%, and the local confidence score for each amino acid (i.e., “the likelihood of each amino acid assignment”) was
≥98%. (B) Ion table showing the calculated mass of possible fragment ions. All fragment ions matching a peak
within the mass error tolerance were colored blue (b-ion series) or red (y ion series). The lower graph shows mass
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error distribution of all matched fragment ions (represented by blue and red dots); Figure S4: High-resolution
fragmentation spectrum of the m/z 959.9163 ion (z = 2; precursor error −1.5 ppm) from HPLC Peak 2 obtained
on a QExactive Plus instrument (A). The peptide sequence was interpreted by the PEAKS 8 de novo sequencing
software. The average local confidence was set to 99%, and the local confidence score for each amino acid
(i.e., “the likelihood of each amino acid assignment”) was ≥ 98%. (B) Ion table showing the calculated
mass of possible fragment ions. All fragment ions matching a peak within the mass error tolerance were
colored blue (b-ion series) or red (y ion series). The lower graph shows mass error distribution of all matched
fragment ions (represented by blue and red dots); Figure S5: High-resolution fragmentation spectrum of the m/z
902.4039 ion (z = 2; precursor error −0.4 ppm) from HPLC Peak 2 obtained on a QExactive Plus instrument (A).
The peptide sequence was interpreted by the PEAKS 8 de novo sequencing software. The average local confidence
was set to 99%, and the local confidence score for each amino acid (i.e., “the likelihood of each amino acid
assignment”) was ≥98%. (B) Ion table showing the calculated mass of possible fragment ions. All fragment ions
matching a peak within the mass error tolerance were colored blue (b-ion series) or red (y ion series). The lower
graph shows mass error distribution of all matched fragment ions (represented by blue and red dots); Figure S6:
High-resolution fragmentation spectrum of the m/z 709.6204 ion (z = 3; precursor error −1.7 ppm) from HPLC
Peak 2 obtained on a QExactive Plus instrument (A). The peptide sequence was interpreted by the PEAKS 8 de
novo sequencing software. The average local confidence was 91%, and the local confidence score for each amino
acid (i.e., “the likelihood of each amino acid assignment”) is shown in the yellow inset. (B) Ion table showing the
calculated mass of possible fragment ions. All fragment ions matching a peak within the mass error tolerance
were colored blue (b-ion series) or red (y ion series). The lower graph shows mass error distribution of all matched
fragment ions (represented by blue and red dots); Figure S7: Sequence coverage of mature BlatPII-c showing
de novo sequenced tryptic peptides from HPLC Peak 1 with average local confidence (ALC) ≥99%, according
to PEAKS 8 De Novo software. MS data were acquired using a Q Exactive Plus high resolution instrument.
The similarity-based alignment was performed by the PepExplorer software, using the following search
parameters: minimum identity = 75%; minimum number of residues per peptide = 6; substitution
matrix = PAM30MS. Under these conditions, the sequence coverage obtained for BlatPII-c was 22.1%; Figure S8:
Sequence coverage of mature BlatPII-c showing de novo sequenced tryptic peptides from HPLC Peak 2 with
average local confidence (ALC) ≥99%, according to PEAKS 8 De Novo software. MS data were acquired using a
Q Exactive Plus high resolution instrument. The similarity-based alignment was performed by the PepExplorer
software, using the following search parameters: minimum identity = 75%; minimum number of residues per
peptide = 6; substitution matrix = PAM30MS. Under these conditions, the sequence coverage obtained for BlatPII-c
was 49.1%.
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